Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is >= 10%?

E. Merola; Alonso T. Gordoa; P. Zhang; T. Al-Toubah; E. Pelle; M. Liu; F. Laskaratos; L. de Mestier; A. Lamarca; J. Hernando; M. Cives; R. van Leeuwaarde

Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is >= 10%?

E. Merola, Alonso T. Gordoa, P. Zhang, T. Al-Toubah, E. Pelle, M. Liu, F. Laskaratos, L. de Mestier, A. Lamarca, J. Hernando, M. Cives, R. van Leeuwaarde

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	197-197
Journal	Neuroendocrinology
Volume	110
Publication status	Published - Mar 2020

Keywords

pancreatic net
somatostatin analogs
grade 2 and 3
safety
efficacy

Cite this

@article{06a3ae22a9364d03a0592c9d90ec3a1f,

title = "Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is >= 10%?",

keywords = "pancreatic net, somatostatin analogs, grade 2 and 3, safety, efficacy",

author = "E. Merola and Gordoa, {Alonso T.} and P. Zhang and T. Al-Toubah and E. Pelle and M. Liu and F. Laskaratos and {de Mestier}, L. and A. Lamarca and J. Hernando and M. Cives and {van Leeuwaarde}, R.",

year = "2020",

month = mar,

language = "English",

volume = "110",

pages = "197--197",

journal = "Neuroendocrinology",